SCCM Resource Library-Beyond Procalcitonin: Emerging Biomarkers for Sepsis

Video Transcription

Video Summary

In this video, the speaker discusses the potential role of biomarkers in sepsis. They explain that biomarkers can be used to help with diagnosis, determine the type of infection (bacterial or viral), guide antibiotic use, predict prognosis, and decide on the site of care. The speaker highlights the biomarker procalcitonin, which has been extensively studied and has shown promise in guiding the duration of antibiotic therapy. They also mention other biomarkers such as pancreatic stone protein, pentraxin, and presepsin, which are being studied for their potential use in sepsis. The speaker emphasizes the importance of using multiple biomarkers in combination with clinical assessment, as no single biomarker can provide all the necessary information. They also discuss the potential use of biomarkers in managing patients with COVID-19 and reducing unnecessary antibiotic use. Overall, biomarkers have the potential to improve sepsis management, but more research is needed to fully understand their role.

Asset Subtitle

Sepsis, 2023

Asset Caption

Type: one-hour concurrent | Challenges in Sepsis Prediction and Prognosis (SessionID 1228529)

Meta Tag

Content Type Presentation

Knowledge Area Sepsis

Membership Level Professional

Membership Level Select

Tag Sepsis

Year 2023

Keywords

biomarkers

sepsis

diagnosis

antibiotic therapy

procalcitonin

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.